The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis

Inclusion criteria

• Signed and dated informed consent form
• Good general health
• Male or female subjects aged >21 years old
• Availability for the 9 week duration of the study
• Chronic periodontal disease on natural teeth characterized by the presence of at least 2 teeth with periodontal pockets of 5-9 mm in depth (potential target teeth) demonstrating bleeding on probing without involving the apex of the tooth and confirmed by dental X-ray.
• Females of childbearing potential must be non-pregnant and non-lactating at entry and agree to use an adequate method (Oral or parenteral hormonal contraceptive; Intrauterine device; barrier and spermicide) of birth control during the study.

Exclusion criteria

• An existing aggressive periodontitis.
• Presence of oral local mechanical factors that could (in the opinion of the investigator) influence the outcome of the study.
• Presence of orthodontic appliances, or any removable appliances, that impinge on the tissues being assessed.
• Soft or hard tissue tumours of the oral cavity.
• Presence of dental implant adjacent to target tooth.
• Presence of more than 2 adjacent periodontal pockets on the same potential target tooth.
• Periodontal pockets of more than 9 mm in depth, and/or with class 2 or 3 furcation involvement, on the potential target tooth.
• Systemic antibiotic therapy or periodontal/mechanical/local delivery therapy within 6 weeks prior to study entry and throughout the study duration.
• History of allergy to chlorhexidine, flurbiprofen or to other non-steroidal anti-inflammatory drugs (NSAIDs).
• Subjects taking Phenytoin, calcium channel blockers drugs (CCBs) and/or cyclosporine, which might influence the pattern of tissue response.
• Subjects treated with non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to entry into the study and throughout the study duration.
• Presence of the following conditions: Type 1 diabetes, major recurrent aphtae, stomatitis, abscesses and related oral pathologies.
• The presence of any medical or psychiatric condition that in the opinion of the investigator could affect the successful participation of the subject in the study.
• Subject participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.
• Subject uses chlorhexidine oral rinses/ mouthwashes on a regular basis.